(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 25.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Ionis Pharmaceuticals's revenue in 2026 is $1,058,189,000.On average, 26 Wall Street analysts forecast IONS's revenue for 2026 to be $139,463,418,383, with the lowest IONS revenue forecast at $123,799,833,325, and the highest IONS revenue forecast at $157,926,551,139. On average, 24 Wall Street analysts forecast IONS's revenue for 2027 to be $248,224,359,112, with the lowest IONS revenue forecast at $195,836,128,860, and the highest IONS revenue forecast at $356,801,858,404.
In 2028, IONS is forecast to generate $340,440,865,360 in revenue, with the lowest revenue forecast at $233,846,516,740 and the highest revenue forecast at $525,369,665,524.